#USA #Genetic Testing #Providence, Rhode Island #Nabsys #Genome Mapping

Nabsys and Indiana University: Pioneering the Future of Genome Mapping

In a groundbreaking move towards cancer research, Nabsys 2.0, LLC has announced a multi-year collaboration with the Indiana University School of Medicine, centered on the innovative applications of electronic genome mapping (EGM). This collaboration marks a significant leap in understanding hematologic malignancies, primarily focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

The Collaboration's Objective

Under the guidance of Dr. Kevin T.A. Booth, an Assistant Professor and Clinical Laboratory Director at Indiana University, the collaboration aims to evaluate the OhmX™ Platform. This platform utilizes electronic genome mapping technology to enhance the detection of structural variations that play a critical role in various hematologic conditions. The expectation is not only to deepen the understanding of AML and MDS but also to explore additional abnormalities that could exist in other hematologic malignancies and constitutional disorders.

The Importance of Structural Variation in Cancer Genomics

Structural variation is a significant area of concern in cancer genomics. Traditional methods, such as fluorescence in situ hybridization (FISH) and karyotyping, often fall short due to their limited genomic coverage and lower resolution. Nabsys and Indiana University's collaboration is set to explore how EGM technology can provide a complementary approach to these existing methods. By doing so, they hope to enhance existing cytogenetic workflows and offer new insights into the complexities of genomic abnormalities.

Transforming Genome Analysis with the OhmX™ Platform

The OhmX™ Platform is a revolutionary tool that uses advanced electronic detection methods to analyze ultra-long DNA molecules. This technology replaces the need for expensive optical systems, presenting a compact and cost-effective solution capable of delivering high-resolution analysis of structural variants and copy number alterations. With the goal of democratizing access to genomic analysis, Nabsys envisions that this technology will empower laboratories worldwide by delivering vital genomic insights that can inform critical research and treatment strategies.

Expert Insights

Barrett Bready, M.D., the founder and CEO of Nabsys, commented on the collaboration: "Indiana University has made significant strides in cytogenetics and molecular genetics, making this partnership an ideal fit as we further develop electronic genome mapping applications. This collaboration represents a key advancement toward addressing the intricate challenges related to structural variant analysis."

Dr. Booth echoed this sentiment, remarking, "Structural variation remains one of the most important yet technically challenging aspects of cancer genomics. Collaborating with Nabsys provides a unique opportunity to utilize Electronic Genome Mapping to deepen our understanding of AML and MDS, potentially uncovering insights that can reshape our approach to cancer research."

Upcoming Engagements

As part of their ongoing efforts, Nabsys will be participating in the Cancer Genomics Consortium (CGC) Annual Meeting from August 1–5, 2026, held in Houston, Texas. During this event, Nabsys plans to present research that underscores the advancements made in Electronic Genome Mapping applications for hematologic malignancies. This will include an oral presentation and several scientific posters showcasing the potential of EGM methodology in delivering comprehensive genomic insights.

Conclusion

The partnership between Nabsys and Indiana University signifies a promising advancement in genome mapping technology, potentially revolutionizing how hematologic malignancies are studied. By harnessing the capabilities of electronic genome mapping, researchers and clinicians aim to enhance their understanding of complex genetic variations, ultimately leading to better patient outcomes in cancer treatment. For more details about Nabsys and their innovative OhmX™ Platform, visit Nabsys website.